Background: There is increasing pressure for specialization of medical serv
ices. The effect of surgical specialization on the outcome of breast cancer
in Bedford has been assessed.
Methods: The Bedford Breast Cancer Registry, which contains prospective dia
gnostic, treatment and follow-up data on all breast cancers treated in Nort
h Bedfordshire, was analysed to compare breast cancer outcome between 1990-
1992 and 1993-1996, that is before and after the advent of surgical subspec
ialization. All 784 patients were analysed, including patients with metasta
ses (4 per cent) and those treated by tamoxifen alone (8 per cent). Outcome
was compared in terms of disease-free survival (DFS), locoregional and all
(locoregional and metastases) recurrence rates assessed by Cox proportiona
l hazard and Kaplan-Meier analyses.
Results: Overall DFS was 75 per cent and the locoregional recurrence rate w
as 8 per cent at 3 years. The tumour stage and grade at presentation and th
e proportion of screen-detected cancers were similar for both intervals. Th
e outcome for patients before specialization (1990-1992; n=329) was worse:
hazard ratio (HR) for DFS 1.5 (95 per cent confidence interval 1.2-2.0) and
HR for locoregional recurrence 2.0 (1.2-3.5). After subspecialization (199
3-1996, n=455) DFS improved from 70 to 79 per cent (P=0.009) and the all re
currence rate fell from 22 to 12 per cent (P=0.0004) at 3 years. The improv
ement in outcome was mainly in younger patients (aged less than 70 years),
in whom DFS improved from 72 to 81 per cent (P=0.02) and the all recurrence
rate fell from 24 to 12 per cent (P=0 001) at 3 years. The improvement was
associated with increased axillary surgery (47 to 74 per cent; P<0.0001),
and more frequent use of tamoxifen (74 to 84 per cent; P=0.004) and chemoth
erapy (10 to 27 per cent; P<0.0001)in this age group.
Conclusion: There was a significant improvement in outcome for patients wit
h breast cancer after surgical subspecialization in Bedford. This may relat
e to the more frequent use of appropriate systemic therapy.